Literature DB >> 12791659

Localization of BCR-ABL to F-actin regulates cell adhesion but does not attenuate CML development.

Jason A Wertheim1, Samanthi A Perera, Daniel A Hammer, Ruibao Ren, David Boettiger, Warren S Pear.   

Abstract

We have previously found that P210BCR-ABL increases the adhesion of hematopoietic cell lines to fibronectin by a mechanism that is independent of tyrosine kinase activity. To investigate the pathway(s) by which P210BCR-ABL influences cell adhesion, we used a quantitative cell adhesion device that can discern small changes in cell adhesion to assay P210BCR-ABL with mutations in several critical domains. We expressed P210BCR-ABL mutants in 32D myeloblast cells and found that binding to fibronectin is mediated primarily by the alpha5beta1 integrin. We performed a structure/function analysis to map domains important for cell adhesion. Increased adhesion was mediated by 3 domains: (1) the N-terminal coiled-coil domain that facilitates oligomerization and F-actin localization; (2) bcr sequences between aa 163 to 210; and (3) F-actin localization through the C-terminal actin-binding domain of c-abl. We compared our adhesion results with the ability of these mutants to cause a chronic myelogenous leukemia (CML)-like disease in a murine bone marrow transplantation assay and found that adhesion to fibronectin did not correlate with the ability of these mutants to cause CML. Together, our results suggest that F-actin localization may play a pivotal role in modulating adhesion but that it is dispensable for the development of CML.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12791659     DOI: 10.1182/blood-2003-01-0062

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  14 in total

Review 1.  BCR-ABL truncation due to premature translation termination as a mechanism of resistance to kinase inhibitors.

Authors:  Wanlong Ma; Hagop Kantarjian; Chen-Hsiung Yeh; Zhong J Zhang; Jorge Cortes; Maher Albitar
Journal:  Acta Haematol       Date:  2009-03-31       Impact factor: 2.195

2.  Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis.

Authors:  J A Cutler; R Tahir; S K Sreenivasamurthy; C Mitchell; S Renuse; R S Nirujogi; A H Patil; M Heydarian; X Wong; X Wu; T-C Huang; M-S Kim; K L Reddy; A Pandey
Journal:  Leukemia       Date:  2017-02-17       Impact factor: 11.528

3.  Expression of the IFNAR1 chain of type 1 interferon receptor in benign cells protects against progression of acute leukemia.

Authors:  Bin Zhao; Sabyasachi Bhattacharya; Qiujing Yu; Serge Y Fuchs
Journal:  Leuk Lymphoma       Date:  2017-05-15

Review 4.  Molecular and cellular bases of chronic myeloid leukemia.

Authors:  Yaoyu Chen; Cong Peng; Dongguang Li; Shaoguang Li
Journal:  Protein Cell       Date:  2010-02-06       Impact factor: 14.870

Review 5.  Alternative approaches to eradicating the malignant clone in chronic myeloid leukemia: tyrosine-kinase inhibitor combinations and beyond.

Authors:  Wesam Ahmed; Richard A Van Etten
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2013

6.  Bcr-Abl induces abnormal cytoskeleton remodeling, beta1 integrin clustering and increased cell adhesion to fibronectin through the Abl interactor 1 pathway.

Authors:  Yingzhu Li; Nancy Clough; Xiaolin Sun; Weidong Yu; Brian L Abbott; Christopher J Hogan; Zonghan Dai
Journal:  J Cell Sci       Date:  2007-03-27       Impact factor: 5.285

Review 7.  Rac GTPases as key regulators of p210-BCR-ABL-dependent leukemogenesis.

Authors:  E K Thomas; J A Cancelas; Y Zheng; D A Williams
Journal:  Leukemia       Date:  2008-03-20       Impact factor: 11.528

Review 8.  Signal transduction in the chronic leukemias: implications for targeted therapies.

Authors:  Wesam Ahmed; Richard A Van Etten
Journal:  Curr Hematol Malig Rep       Date:  2013-03       Impact factor: 3.952

9.  Abelson kinase acts as a robust, multifunctional scaffold in regulating embryonic morphogenesis.

Authors:  Edward M Rogers; Andrew J Spracklen; Colleen G Bilancia; Kaelyn D Sumigray; S Colby Allred; Stephanie H Nowotarski; Kristina N Schaefer; Benjamin J Ritchie; Mark Peifer
Journal:  Mol Biol Cell       Date:  2016-07-06       Impact factor: 4.138

10.  Gads (Grb2-related adaptor downstream of Shc) is required for BCR-ABL-mediated lymphoid leukemia.

Authors:  L C Gillis; D M Berry; M D Minden; C J McGlade; D L Barber
Journal:  Leukemia       Date:  2013-02-12       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.